Akademik Veri Yönetim Sistemi
12th International Conference on Biotechnology and Bioengineering & 6th International Conference on Agricultural and Food Science, Modena, İtalya, 28 - 30 Eylül 2022, ss.49
SARS-CoV-2, which caused the World Health Organization (WHO) to declare an international public health
emergency, had infected more than 574 million people and killed more than 6.3 million people as of August
3, 2022. As a result of the development of protective vaccines against the disease, 11 vaccines were approved
by the WHO and 40 vaccines were approved for use in humans by different countries. In 2021, inactivated
vaccines constituted 4.16 billion doses of total vaccine production as 11.15 billion doses for Covid-19. This
amount (approximately 37%) underlines the importance of inactivated vaccines in pandemic conditions. The
first step in the inactivated vaccine process is the production of live virus. Investigation of SARS-CoV-2 virus
production in bioreactor systems, is important for determining the efficient system. The aim of this study was
to comperate the production of SARS-CoV-2 antigen by Vero cells in Cell Factory (CF) system for static
culture and microcarrier (MC) spinner flask system for suspension culture. After virus production, antigen
content of the pellet obtained by PEG precipitation of the clarified culture was determined by SDS-PAGE
method. According to the first study results, cellular production yields were 0.26 μg antigen/106 cells in the
CF system and 0.20 μg antigen/106 cells in the MC system. In second virus production for purification studies,
antigen yields were 756.7 μg antigen/liter and 0.39 μg antigen/106 cells. The PEG pellet was purified
comparatively in AKTA pure-150 system by using flow-through (Capto Core 400, CC400, Cytiva) and bindelute
(Nuvia HP-Q, Bio-Rad) principles. According to the purification results, the antigen yield was 89% for
CC400 and 74% for Nuvia HP-Q. CC400, was better about removal of impurities as well. As a result, Cell
Factory system was found more efficient for lab-scale SARS-CoV-2 antigen production and CC400 column
gave the best results for the purification process.